UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of: April 2019
Commission File Number: 001-37847
MOTIF BIO PLC
(Exact name of registrant as specified in its charter)
125 Park Avenue
25th Floor
New York, New York 10017
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-Fý Form 40-F¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___ |
| |
| | | | |
MOTIF BIO PLC
FORM 6-K
Motif Bio announces appointment of andrew powell to board of Directors
On April 26, 2019 Motif Bio plc (the “Company”) issued a press release announcing the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately.The press release is attached hereto as Exhibits 99.1.
Notice of Annual General meeting
On April 26, 2019, issued a press release announcing that its Annual General Meeting (AGM) is to be held at 1 PM BST on 22 May 2019 at the offices of DLA Piper UK LLP at 160 Aldersgate Street London EC1A 4HT, United Kingdom.The press release is attached hereto as Exhibits 99.2.
TheNotice of the AGM, Proxy Form for General Meeting and Letter to Shareholders that have or deemed to have elected to receive electronic communications will be available later today on the Investors section of the Company’s website atwww.motifbio.com. The Notice of AGM, Proxy Form for General Meeting and Letter to Shareholders are attached hereto as Exhibits 99.3, 99.4 and 99.5, respectively.
The information contained in this report on Form 6-K, including Exhibits 99.1 to 99.5, is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibits
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MOTIF BIO PLC |
| | |
| | By:/s/ Graham Lumsden |
| | Name: Graham Lumsden |
| | Title: Chief Executive Officer |
Date: April 26, 2019
